参考文献/References:
[1] Farmer TD,Jenkins EC,O'Brien TP,et al.Comparison of the physiological relevance of systemic vs.portal insulin delivery to evaluate whole body glucose flux during an insulin clamp[J].Am J Physiol Endocrinol Metab,2015,308(3):E206-222.DOI:10.1152/ajpendo.00406.2014.
[2] Wong CY,Martinez J,Dass CR.Oral delivery of insulin for treatment of diabetes:status quo, challenges and opportunities[J].J Pharm Pharmacol,2016,68(9):1093-1108.DOI:10.1111/jphp.12607.
[3] Xiao Y,Tang Z,Wang J,et al.Oral insulin delivery platforms:strategies to address the biological barriers[J].Angew Chem Int Ed Engl,2020,59(45):19787-19795.DOI:10.1002/anie.202008879.
[4] Heise T,Plum-Mörschel L,Zijlstra E.Oral insulin:a history of ambition,failure and data torturing[J].Diabetes Obes Metab,2023,25(4):940-942.DOI:10.1111/dom.14984.
[5] 姚晟瑜,樊星砚,江宽,等.胰岛素口服给药的困境与突破[J].药学学报,2020,55(7):1549-1561.DOI:10.16438/j.0513-4870.2020-0913.
[6] Sheng J,He H,Han L,et al.Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates[J].J Control Release,2016,233:181-190.DOI:10.1016/j.jconrel.2016.05.015.
[7] Shah D,Shen WC.Transcellular delivery of an insulin-transferrin conjugate in enterocyte-like Caco-2 cells[J].J Pharm Sci,1996,85(12):1306-1311.DOI:10.1021/js9601400.
[8] Wang M,Wang C,Ren S,et al.Versatile oral insulin delivery nanosystems:from materials to nanostructures[J].Int J Mol Sci,2022,23(6).DOI:10.3390/ijms23063362.
[9] Pang H,Huang X,Xu ZP,et al.Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes[J].Drug Discov Today,2023,28(1):103393.DOI:10.1016/j.drudis.2022.103393.
[10] Vanea E,Moraru C,Vulpoi A,et al.Freeze-dried and spray-dried zinc-containing silica microparticles entrapping insulin[J].J Biomater Appl,2014,28(8):1190-1199.DOI:10.1177/0885328213501216.
[11] Situ W,Chen L,Wang X,et al.Resistant starch film-coated microparticles for an oral colon-specific polypeptide delivery system and its release behaviors[J]. J Agric Food Chem,2014,62(16):3599-3609.DOI:10.1021/jf500472b.
[12] Yang Y,Liu Y,Chen S,et al.Carboxymethyl β-cyclodextrin grafted carboxymethyl chitosan hydrogel-based microparticles for oral insulin delivery[J].Carbohydr Polym,2020,246:116617.DOI:10.1016/j.carbpol.2020.116617.
[13] Yazdi JR,Tafaghodi M,Sadri K,et al.Folate targeted PEGylated liposomes for the oral delivery of insulin:in vitro and in vivo studies[J].Colloids Surf B Biointerfaces,2020,194:111203.DOI: 10.1016/j.colsurfb.2020.111203.
[14] Han X,Lu Y,Xie J,et al.Zwitterionic micelles efficiently deliver oral insulin without opening tight junctions[J].Nat Nanotechnol,2020,15(7):605-614.DOI:10.1038/s41565-020-0693-6.
[15] Lin PY,Chuang EY,Chiu YH,et al.Safety and efficacy of self-assembling bubble carriers stabilized with sodium dodecyl sulfate for oral delivery of therapeutic proteins[J].J Control Release,2017,259:168-175.DOI:10.1016/j.jconrel.2016.12.018.
[16] Kurtzhals P,Nishimura E,Haahr H,et al.Commemorating insulin's centennial:engineering insulin pharmacology towards physiology[J].Trends Pharmacol Sci,2021,42(8):620-639.DOI:10.1016/j.tips.2021.05.005.
[17] Zizzari AT,Pliatsika D,Gall FM,et al.New perspectives in oral peptide delivery[J].Drug Discov Today,2021,26(4):1097-1105.DOI:10.1016/j.drudis.2021.01.020.
[18] Strachan JB,Dyett B,Chan S,et al.A promising new oral delivery mode for insulin using lipid-filled enteric-coated capsules[J].Biomater Adv,2023,148:213368.DOI:10.1016/j.bioadv.2023.213368.
[19] Abramson A,Caffarel-Salvador E,Khang M,et al.An ingestible self-orienting system for oral delivery of macromolecules[J].Science,2019,363(6427):611-615.DOI:10.1126/science.aau2277.
[20] Abramson A,Frederiksen MR,Vegge A,et al.Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors[J].Nat Biotechnol,2022,40(1):103-109.DOI:10.1038/s41587-021-01024-0.
[21] Abramson A,Caffarel-Salvador E,Soares V,et al.A luminal unfolding microneedle injector for oral delivery of macromolecules[J].Nat Med,2019,25(10):1512-1518.DOI:10.1038/s41591-019-0598-9.
[22] Halberg IB,Lyby K,Wassermann K,et al.Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes:a randomised,double-blind, phase 2 trial[J].Lancet Diabetes Endocrinol,2019,7(3):179-188.DOI:10.1016/s2213-8587(18)30372-3.
[23] Lebovitz HE,Fleming A,Cherrington AD,et al.Efficacy and safety of Tregopil,a novel,ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes:a randomized,active-controlled phase 2/3 study[J].Expert Opin Pharmacother,2022,23(16):1855-1863.DOI:10.1080/14656566.2022.2141569.
相似文献/References:
[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(01):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(01):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(01):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制
——2014年美国糖尿病协会“杰出科学成就奖”
演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(01):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(01):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(01):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(01):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(01):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(01):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]